W-13 . hydrochloride

Calmodulin antagonist. PDE and MLCK inhibitor.



ALX-270-156-M005	5 mg	39.00 USD

ALX-270-156-M025	25 mg	156.00 USD

Antagonist of calmodulin, inhibiting activation of Ca²⁺/calmodulin-dependent phosphodiesterase (PDE I) and myosin light chain kinase.

Product Specification

Alternative Name:	N-(4-Aminobutyl)-5-chloro-2-naphthalenesulfonamide . HCl

Identity:	Identity determined by ¹H-NMR.

Formula:	C₁₄H₁₇ClN₂O₂S . HCl

MW:	312.8 . 36.5

Purity:	≥98%

Appearance:	White to beige solid.

CAS:	88519-57-7

Source/Host:	Synthetic.

Solubility:	Soluble in water (warm) or methanol.

Long Term Storage:	-20°C

Handling:	Protect from light.

Please mouse over

Product Literature References

Tamoxifen-resistant human breast cancer cell growth: inhibition by thioridazine, pimozide and the calmodulin antagonist, W-13: J.S. Stroble & V.A. Peterson; J. Pharm. Exp. Ther. 263, 186 (1992), Abstract;

Direct interaction of calmodulin antagonists with Ca2+/calmodulin- dependent cyclic nucleotide phosphodiesterase: H. Itoh & H. Hidaka; J. Biochem. 96, 1721 (1984), Abstract;

Calmodulin antagonists enhance calcium binding to calmodulin: M. Inagaki, et al.; Pharmacology 27, 125 (1983), Abstract;

Naphthalenesulfonamides as calmodulin antagonists: H. Hidaka & T. Tanaka; Meth. Enzymol. 102, 185 (1983), Abstract;

Activity-structure relationship of calmodulin antagonists, Naphthalenesulfonamide derivatives: H. Hidaka, et al.; Mol. Pharmacol. 20, 571 (1981), Abstract;

[Pharmacology of calmodulin: calmodulin antagonist (author's transl)]: H. Hidaka; Prot. Nucl. Acid Enz. 26, 977 (1981), Abstract;

Hydrophobic regions function in calmodulin-enzyme(s) interactions: T. Tanaka & H. Hidaka; J. Biol. Chem. 255, 11078 (1980), Abstract; Full Text